AngioDynamics (ANGO) Set to Announce Quarterly Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) will be posting its quarterly earnings results before the market opens on Thursday, October 3rd. Analysts expect AngioDynamics to post earnings of ($0.15) per share for the quarter. AngioDynamics has set its FY25 guidance at ($0.42)-($0.38) EPS and its FY 2025 guidance at -0.420–0.380 EPS.Parties interested in participating in the company’s conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $71.00 million during the quarter, compared to the consensus estimate of $70.86 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The firm’s quarterly revenue was down 22.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.02 earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $7.63 on Wednesday. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $8.25. The stock has a market cap of $305.62 million, a PE ratio of -1.57 and a beta of 0.65. The firm’s fifty day moving average price is $7.52 and its two-hundred day moving average price is $6.60.

Analyst Upgrades and Downgrades

ANGO has been the topic of several research reports. Canaccord Genuity Group lowered their price objective on shares of AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.25.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.